Skip to main content

Table 1 Demographic and clinical variables for patient with early arthritis and established RA

From: Differential glucocorticoid metabolism in patients with persistent versus resolving inflammatory arthritis

Outcome group Early resolving arthritis Early persistent arthritis (All) Early persistent RA Established RA P
Number 24 31 18 20 na
Female 16 (67%) 21 (68%) 12 (67%) 15 (75%) ns
n (%)
Age, years; mean (SD) 51.8 (14.4) 56.9 (18.2) 60.72 (15.8) 58.2 (14.3) ns
CRP, mg/l; 8 (0-14) 25 (10-44) 27 (10.75-68) 9 (0-44.75) P = 0.0221 Early p arthritis (all) vs early resolving arthritis
Median (IQR) P = 0.0184 Early p RA vs early resolving arthritis
ESR, mm/h; 20.5 (12-44.75) 26 (20-60.75) 24 (19.75-60.75) 25 (9.75-48.75) ns
Median (IQR)
DAS28, ESR; 3.7 (3.5-5.1) 5.3 (4.4-6.7) 6.1 (4.25-6.8) 5.3 (4.3-6.1) P = 0.0013 Early p arthritis (all) vs early resolving arthritis
Median (IQR) P = 0.0054 Early p RA vs early resolving arthritis
Disease duration, weeks; 6.5 (4-9.5) 8 (6-10) 8 (5.75-10) 42 (22.25-82.5) P < 0.0001 Established RA vs early p RA
Median (IQR)
Tender joint count 28; 2.5 (1-4.75) 7 (2-17) 8.5 (2.75-15.5) 8.5 (4.25-19.75) P = 0.0072 Early p arthritis (all) vs early resolving arthritis
Median (IQR) P = 0.0072 Early p RA vs early resolving arthritis
Swollen joint count 28; 1 (1-3.5) 4 (1-11) 6.5 (3-13) 7 (4-13.5) P = 0.0034 Early p arthritis (all) vs early resolving arthritis
Median (IQR) P = 0.0001 Early p RA vs early resolving arthritis
RF + ve 3 (12.5%) 10 (32%) 9 (50%) 8 (40%) ns
n (%)
Anti-CCP antibodies 0 (0%) 9 (29%) 8 (44%) 11 (55%) P = 0.0004
n (%)
  1. Early arthritis patients were assigned to one of the following three outcome groups after clinical follow-up: resolving arthritis (column 2), persistent arthritis (column 3) and persistent RA (column 4; a subgroup of the persistent arthritis patients). In addition, data are shown for patients who presented with established RA (column 5). Data shown for normally distributed variables are mean (SD) values and for non-normally distributed variables are median (IQR) values. Comparisons between different outcome groups for normally distributed clinical characteristics were carried out using the unpaired t test and comparison between different outcome groups for non-normally distributed clinical characteristics were carried out using the Mann-Whitney test (early persistent arthritis (all) vs early resolving arthritis; early persistent RA vs early resolving arthritis; early persistent RA vs established RA). Comparisons between different outcome groups for gender and autoantibody status were carried out using the chi-square test. A P value <0.05 was considered statistically significant. RA, rheumatoid arthritis; na, non applicable; ns, non significant; SD, standard deviation; CRP, C-reactive protein; IQR, interquartile range; ESR, erythrocyte sedimentation rate; DAS28, ESR, 28-item disease activity score calculated using ESR; RF, rheumatoid factor; anti-CCP antibodies, anti-cyclic citrullinated peptide antibodies.